4-(4-Chlorophenyl)1-[3-(5-cyano-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 4-(4-Chlorophenyl)1-[3-(5-cyano-5H-dibenzo[a,d]cycloheptene-5-yl)propyl]piperidin-4-ol
• 英文别名: 5-[3-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]propyl]-5H-dibenzo[a,d]cycloheptene-5-carbonitrile；5-{3-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-propyl}-5H-dibenzo[a,d]cycloheptene-5-carbonitrile；2-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propyl]tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carbonitrile
• 化学式: C₃₀H₂₉ClN₂O
• 分子量: 469.026
• InChiKey: JXQNWHHDGDWBTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  47.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Methods of Inhibiting Metastasis from Cancer
  申请人：Salvino Joseph M.

  公开号：US20120141471A1

  公开（公告）日：2012-06-07

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.

  本发明涉及一种用于预防或治疗被诊断为癌症的患者中的转移的组合物。本发明还包括一种用于预防或治疗被诊断为癌症的患者中的转移的方法，其中该方法包括向需要该药物的患者投与至少一种药用制剂，该制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。
• Chemokine receptor antagonists and methods of use therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20020151553A1

  公开（公告）日：2002-10-17

  Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by the following structural formula: 1 and physiologically acceptable salts thereof. Z is a cycloalkyl or non-aromatic heterocyclic ring group fused to one or more carbocyclic aromatic rings and/or heteroaromatic rings, wherein each ring in Z is independently substituted or unsubstituted; Y is a covalent bond, —O— or —CO—; n is an integer from one to about five; X is a covalent bond or —CO—; and M is >NR 2 , >CR 1 R 2 ; R 1 is —H, —OH, an aliphatic group, —O—(aliphatic group), —SH or —S—(aliphatic group); R 2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.

  本发明涉及一种治疗与异常白细胞招募和/或激活相关的疾病的方法。该方法包括向患者投与以下结构式所表示的化合物的治疗有效量及其生理上可接受的盐：1 其中，Z是一个环烷基或非芳香族杂环环基，与一个或多个碳环芳香族环和/或杂环芳香族环融合，其中Z中的每个环都是独立取代或未取代的；Y是共价键，-O-或-CO-；n是从1到约5的整数；X是共价键或-CO-；M是> NR2，> CR1R2；R1是-H，-OH，脂肪基，-O-（脂肪基），-SH或-S-（脂肪基）；R2是脂肪基，取代脂肪基，芳香族基，取代芳香族基，苄基，取代苄基，非芳香族杂环基或取代非芳香族杂环基。
• Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same
  申请人：Drexel University College of Medicine Philadelphia Health & Education Corporation d/b/a

  公开号：US20130156761A1

  公开（公告）日：2013-06-20

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.

  本发明涉及一种对已被诊断患有癌症的受试者预防或治疗转移的有用组合物。本发明还涉及一种预防或治疗已被诊断患有癌症的受试者的转移的方法，其中该方法包括向需要该药物的受试者施用至少一种药物制剂，该药物制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。
• Compounds useful for inhibiting metastasis from cancer and methods using same
  申请人：Drexel University

  公开号：US10414771B2

  公开（公告）日：2019-09-17

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.

  本发明包括可用于预防或治疗确诊癌症患者转移的组合物。本发明还包括预防或治疗被诊断患有癌症的受试者的转移的方法，其中该方法包括向需要该方法的受试者施用有效量的药物制剂，该药物制剂包含至少一种药学上可接受的载体和至少一种CX3CR1或fractalkine拮抗剂。
• US6323206B1
  申请人：——

  公开号：US6323206B1

  公开（公告）日：2001-11-27